Transthyretin-Mediated Amyloidosis

Neurology·MeSH: Amyloidosis

9 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
AMVUTTRA	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ONPATTRO	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
supplemental new drug	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
tegsedi	AKCEA THERAPEUTICS, INC. (AKCA)
wainua	ASTRAZENECA PLC (AZN)

Phase 3(2)

Drug	Company
Nucresiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Vutrisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 1(1)

Drug	Company
ALN-TTRSC04	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Unknown(1)

Drug	Company
inotersen	AKCEA THERAPEUTICS, INC. (AKCA)

BioSniper tracks 9 drugs in development for Transthyretin-Mediated Amyloidosis across 3 companies.

There are 2 clinical trials targeting Transthyretin-Mediated Amyloidosis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.